Business Standard

How future with lower Covid death rate seems like a worthy investment

Unfortunately, turning nasal vaccines into reality has a long way to go. The same is true for any newer approach to combatting Covid

Photo: Unsplash/Mufid Majnun
Premium

Photo: Unsplash/Mufid Majnun

Lisa Jarvis | Bloomberg Opinion
Last week, the Food and Drug Administration’s vaccine advisory committee paved the way for a simpler, flu-like plan for Covid. Everyone, whether they’ve been vaccinated before or not, will get a shot tailored to variants on the virus. And likely, people will get those shots once every fall.
 
The panel’s recommendation was unanimous, but came after lengthy discussion about the limitations of the strategy. Some worried that the omicron-specific shots seem to offer little improvement over the original vaccine, while others were concerned that an annual shot was too frequent for some — or not frequent enough for others, especially

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 29 2023 | 7:41 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com